TRACER (S1415CD) NEWSLETTER







December 2017

STUDY UPDATES

- + As of 12/4/17, we have 1,150 patients registered across 41 components (12 out of 13 Cohort components, 7 out of 8 Usual Care components, 11 out of 12 Intervention Arm 3 components, and 11 out of 12 Intervention Arm 4 components).
- + As of 12/4/17, 23 of our 24 intervention components have completed their order change process and are open for enrollment.

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

CONGRATULATIONS AND THANK YOU TO...

The following sites that have reached 75% of their overall accrual:

- **★** Cancer Center of Kansas in Wichita, KS
- **★** Greenville Memorial Hospital in Greenville, SC
- **★** Illinois CancerCare in Peoria, IL

And a HUGE thank you to Doctors' Cancer Center in Manati, Puerto Rico! Despite the challenges from two recent hurricanes, they have begun accruing patients to TrACER!!

ELIGIBILITY: PRIOR RADIATION THERAPY

Patients who have received prior radiation therapy are eligible for TrACER as long as they meet all other eligibility criteria in Section 5.0.

ACCRUAL GOALS

TrACER is reliant on each component meeting its accrual goal by March 31, 2019. If you are facing barriers to reaching your accrual goal (90 eligible patients RCT arm, 56 eligible patients cohort arm), please get in touch with the TrACER team ASAP to help problem solve.

Contact Us